- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06087458
Phase 1/2 Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration (JOURNEY)
Étude de phase 1/2a sur l'augmentation de la dose de VOY-101 chez des patients atteints de dégénérescence maculaire avancée non néovasculaire liée à l'âge
The Phase 1 safety study of VOY-101 is comprised of escalating dose Cohorts, followed by a Phase 2 at the recommended phase 2 dose.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The study has a prospective, open-label, multi-center, two-part design to evaluate a single, unilateral intravitreal (IVT) injection of VOY-101 in subjects with geographic atrophy (GA), the advanced form of non-neovascular age-related macular degeneration (AMD). Phase 1 followed a standard dose escalation model to establish safety and tolerability of VOY-101 and determine the recommended phase 2 dose. This dose is being used in the randomized Phase 2 part of the study to evaluate the safety and efficacy of VOY-101 in the study eye compared to untreated fellow eye.
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
New South Wales
-
Sydney, New South Wales, Australie, 2000
- Sydney Retina Clinic and Day Surgery
-
-
Victoria
-
East Melbourne, Victoria, Australie, 3002
- Cerulea Clinical Trials
-
-
-
-
-
Haifa, Israël
- Rambam Medical Center
-
Tel Aviv, Israël, 64239
- Tel-Aviv Sourasky Medical Center, Ophthalmology Division
-
-
-
-
Arizona
-
Scottsdale, Arizona, États-Unis, 85255
- Retina Macula Institute of AZ
-
-
California
-
Poway, California, États-Unis, 92064
- Retina Consultants San Diego
-
Sacramento, California, États-Unis, 95825
- Retinal Consultants Medical Group
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02114
- Ophthalmic Consultants of Boston
-
-
Missouri
-
St Louis, Missouri, États-Unis, 63128
- The Retina Institute
-
-
New Jersey
-
Cherry Hill, New Jersey, États-Unis, 08034
- Mid Atlantic Retina
-
-
Oregon
-
Portland, Oregon, États-Unis, 97221
- Retina Northwest
-
-
South Dakota
-
Rapid City, South Dakota, États-Unis, 57701
- Black Hills Regional Eye Institute
-
-
Texas
-
Austin, Texas, États-Unis, 78705
- Austin Research Center for Retina
-
Fort Worth, Texas, États-Unis, 76132
- Star Retina
-
Southlake, Texas, États-Unis, 76092
- Retina Center of Texas
-
-
Utah
-
Salt Lake City, Utah, États-Unis, 84132
- University of Utah John A. Moran Eye Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Are ≥60 years of age at the time of consent.
- Are willing and able to understand and provide written informed consent.
- Are willing and able to return for scheduled treatment and follow-up examinations.
- Are able to undergo ETDRS BCDVA testing and ophthalmic imaging.
- Well-demarcated GA secondary to AMD in the absence of MNV and in the absence of history of MNV for both eyes.
- Absence of signs of non-exudative MNV.
- Additional Ocular Inclusion Criteria for both eyes.
- Meet certain genotype criteria for risk of AMD.
Exclusion Criteria:
- Are women of childbearing potential (WOCBP) and are pregnant or unwilling to use and document use of effective contraception for the duration of the study.
- Additional Systemic, Ocular, and Genetic Exclusion Criteria.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Low
Single, unilateral, intravitreal injection of low dose of VOY-101 |
VOY-101 |
|
Expérimental: Medium
Single, unilateral, intravitreal injection of medium dose of VOY-101 |
VOY-101 |
|
Expérimental: High
Single, unilateral, intravitreal injection of high dose of VOY-101 |
VOY-101 |
|
Expérimental: Higher
Single, unilateral, intravitreal injection of higher dose of VOY-101 |
VOY-101 |
|
Expérimental: Intermediate
Single, unilateral, intravitreal injection of intermediate dose of VOY-101 |
VOY-101 |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Phase 1: To evaluate the safety and tolerability of a single intravitreal injection of escalating doses of VOY-101
Délai: 24 Months
|
Frequency and type of ocular and systemic adverse events and non-serious treatment-emergent adverse events |
24 Months
|
|
Phase 1: Change from Baseline in markers of inflammation
Délai: Baseline to Month 24
|
Change from Baseline in markers of inflammation including anterior chamber cells, vitreous cells, and retinal vasculitis and retinitis. |
Baseline to Month 24
|
|
Phase 1: Establish the recommended Phase 2 dose in subjects with Geographic Atrophy.
Délai: Month 12
|
Determine whether the maximum tolerated dose (MTD) has been reached (as determined by the occurrence of dose-limiting toxicities [DLTs]) and select the RP2D. |
Month 12
|
|
Phase 2: To evaluate the effect of VOY-101 in the study eye compared with untreated fellow eye on change in Geographic Atrophy lesion size.
Délai: 15 Months
|
Change from Baseline in Geographic Atrophy lesion size |
15 Months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Phase 1: To evaluate the effect of VOY-101 on geographic atrophy lesion size and photoreceptors
Délai: Baseline through 24 Months
|
Growth rate of total geographic atrophy lesion size and photoreceptor change |
Baseline through 24 Months
|
|
Phase 1/2: To establish the pharmacokinetic (PK) profile of VOY-101.
Délai: Baseline through 24 Months
|
Change from Baseline for complement levels in aqueous humor |
Baseline through 24 Months
|
|
Phase 1/2: To evaluate the effect of VOY-101 on best corrected distance visual acuity
Délai: 24 Months
|
Change from Baseline in Early Treatment Diabetic Retinopathy Study (ETDRS) BCDVA and Percentage of subjects with <15 letters lost in BCDVA from Treatment |
24 Months
|
|
Phase 1/2: Development of macular neovascularization
Délai: Month 24
|
Incidence, frequency, severity, and timing of development of macular neovascularization |
Month 24
|
|
Phase 2: To further characterize the ocular and systemic safety and tolerability of VOY-101
Délai: 24 Months
|
Frequency of Investigational Product related ocular and systemic adverse events, adverse events of special interest and non-serious treatment-emergent adverse events. |
24 Months
|
|
Phase 2: To evaluate the effect of VOY-101 in the study eye compared with untreated fellow eye on geographic atrophy lesion size and photoreceptors
Délai: Baseline through Month 24
|
Change in geographic atrophy lesion size and rate of photoreceptor loss |
Baseline through Month 24
|
|
Phase 2: To evaluate the effect of VOY-101 on low luminance visual acuity
Délai: Baseline through Month 24
|
Change from Baseline in the change in visual function using Early Treatment Diabetic Retinopathy Study (ETDRS) Low Luminance Visual (LLVA) vision test |
Baseline through Month 24
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Anne Fung, MD, Perceive Biotherapeutics, Inc.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- PBI-AMD-002
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .